Kawai, Akira
Narahara, Hiroyuki
Takahashi, Shunji
Nakamura, Tomoki
Kobayashi, Hiroshi
Megumi, Yasunori
Matsuoka, Toshiyuki
Kobayashi, Eisuke
Article History
Received: 7 October 2021
Accepted: 11 April 2022
First Online: 11 May 2022
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and Good Post-Marketing Study Practice. Approval from Clinical Review and Approval Board at Eisai Co., Ltd., and the ethics committee or institutional review board at each study institute was obtained prior to study initiation. Because this was an observational study based on Good Post-Marketing Study Practice, formal informed consent was waived by Clinical Review and Approval Board at Eisai Co., Ltd.; however, all patients consented to eribulin treatment.
: Not applicable.
: ST has received grants from Eisai Co., Ltd., Novartis Pharma K.K., and Taiho Pharmaceutical Co., Ltd.; and honoraria from Eisai Co., Ltd., Novartis Pharma K.K., and Taiho Pharmaceutical Co., Ltd. EK has received honoraria from Eisai Co., Ltd., Novartis Pharma K.K., and Taiho Pharmaceutical Co., Ltd. All other authors declare that they have no competing interests.